CAN FITE BIOPHARMA LTD-ADR (CANF) Fundamental Analysis & Valuation

NYSEARCA:CANF • US13471N3008

Current stock price

3.03 USD
+0.03 (+1%)
Last:

This CANF fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CANF Profitability Analysis

1.1 Basic Checks

  • CANF had negative earnings in the past year.
  • CANF had a negative operating cash flow in the past year.
  • CANF had negative earnings in each of the past 5 years.
  • CANF had a negative operating cash flow in each of the past 5 years.
CANF Yearly Net Income VS EBIT VS OCF VS FCFCANF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • CANF's Return On Assets of -103.30% is on the low side compared to the rest of the industry. CANF is outperformed by 76.94% of its industry peers.
  • CANF has a Return On Equity of -175.75%. This is in the lower half of the industry: CANF underperforms 68.22% of its industry peers.
Industry RankSector Rank
ROA -103.3%
ROE -175.75%
ROIC N/A
ROA(3y)-88.71%
ROA(5y)-90.16%
ROE(3y)-147.66%
ROE(5y)-155.24%
ROIC(3y)N/A
ROIC(5y)N/A
CANF Yearly ROA, ROE, ROICCANF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CANF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CANF Yearly Profit, Operating, Gross MarginsCANF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CANF Health Analysis

2.1 Basic Checks

  • CANF does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CANF has been increased compared to 1 year ago.
  • Compared to 5 years ago, CANF has more shares outstanding
  • There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CANF Yearly Shares OutstandingCANF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M
CANF Yearly Total Debt VS Total AssetsCANF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -27.51, we must say that CANF is in the distress zone and has some risk of bankruptcy.
  • CANF has a Altman-Z score of -27.51. This is amonst the worse of the industry: CANF underperforms 87.79% of its industry peers.
  • There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.51
ROIC/WACCN/A
WACC8.53%
CANF Yearly LT Debt VS Equity VS FCFCANF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M -10M

2.3 Liquidity

  • A Current Ratio of 3.46 indicates that CANF has no problem at all paying its short term obligations.
  • CANF's Current ratio of 3.46 is in line compared to the rest of the industry. CANF outperforms 42.64% of its industry peers.
  • CANF has a Quick Ratio of 3.46. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
  • CANF's Quick ratio of 3.46 is in line compared to the rest of the industry. CANF outperforms 44.77% of its industry peers.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 3.46
CANF Yearly Current Assets VS Current LiabilitesCANF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CANF Growth Analysis

3.1 Past

  • CANF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.05%, which is quite impressive.
  • The Revenue for CANF has decreased by -39.91% in the past year. This is quite bad
  • Measured over the past years, CANF shows a very negative growth in Revenue. The Revenue has been decreasing by -11.90% on average per year.
EPS 1Y (TTM)45.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.05%
Revenue 1Y (TTM)-39.91%
Revenue growth 3Y-20.63%
Revenue growth 5Y-11.9%
Sales Q2Q%-39.91%

3.2 Future

  • CANF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.99% yearly.
  • The Revenue is expected to grow by 2096.15% on average over the next years. This is a very strong growth
EPS Next Y100%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year290391%
Revenue Next 2Y7542.47%
Revenue Next 3Y2096.15%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CANF Yearly Revenue VS EstimatesCANF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 10B 20B 30B 40B
CANF Yearly EPS VS EstimatesCANF Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2023 2024 2025 -2K -4K -6K -8K -10K

More info and screens

Find the best growth stocksShow best growing peers

1

4. CANF Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CANF. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CANF Price Earnings VS Forward Price EarningsCANF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CANF Per share dataCANF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • CANF's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y25.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CANF Dividend Analysis

5.1 Amount

  • No dividends for CANF!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CANF Fundamentals: All Metrics, Ratios and Statistics

CAN FITE BIOPHARMA LTD-ADR

NYSEARCA:CANF (4/21/2026, 4:10:00 PM)

3.03

+0.03 (+1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-20
Earnings (Next)N/A
Inst Owners1.23%
Inst Owner Change1000%
Ins Owners0.01%
Ins Owner Change0%
Market Cap6.49M
Revenue(TTM)405.00K
Net Income(TTM)-9.83M
Analysts80
Price TargetN/A
Short Float %1.75%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)366012%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.03
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-4.59
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-4.18
FCFYN/A
OCF(TTM)-4.18
OCFYN/A
SpS0.19
BVpS2.61
TBVpS2.61
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -103.3%
ROE -175.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.71%
ROA(5y)-90.16%
ROE(3y)-147.66%
ROE(5y)-155.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.33%
Cap/Sales 0.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 3.46
Altman-Z -27.51
F-Score2
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)31.03%
Cap/Depr(5y)47.19%
Cap/Sales(3y)0.5%
Cap/Sales(5y)0.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.05%
EPS Next Y100%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-39.91%
Revenue growth 3Y-20.63%
Revenue growth 5Y-11.9%
Sales Q2Q%-39.91%
Revenue Next Year290391%
Revenue Next 2Y7542.47%
Revenue Next 3Y2096.15%
Revenue Next 5YN/A
EBIT growth 1Y-22.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.18%
OCF growth 3YN/A
OCF growth 5YN/A

CAN FITE BIOPHARMA LTD-ADR / CANF Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CAN FITE BIOPHARMA LTD-ADR?

ChartMill assigns a fundamental rating of 3 / 10 to CANF.


What is the valuation status for CANF stock?

ChartMill assigns a valuation rating of 1 / 10 to CAN FITE BIOPHARMA LTD-ADR (CANF). This can be considered as Overvalued.


What is the profitability of CANF stock?

CAN FITE BIOPHARMA LTD-ADR (CANF) has a profitability rating of 0 / 10.


What is the financial health of CAN FITE BIOPHARMA LTD-ADR (CANF) stock?

The financial health rating of CAN FITE BIOPHARMA LTD-ADR (CANF) is 6 / 10.